CombiGene approved for listing on Nasdaq First North Stockholm and first day of trading is Wednesday 19 December 2018
CombiGene featured in an article in Nature, one of the world’s leading scientific journals
Interim Report January – September 2018
CombiGene’s rights issue registered – BTU converted to shares and warrants
CombiGene: Warrants commence trading
Extraordinary General Meeting of shareholders in CombiGene AB (publ) 2018
Clarification of information concerning new issue
CombiGene closer to clinical trials after oversubscribed issue
Disclosure notice
CombiGene’s preference issue, amounting to 31 million kronor, oversubscribed
CombiGene publishes the prospectus for the rights issue
CombiGene AB (publ) (”CombiGene” or ”the Company”) publishes this prospectus pursuant to a resolution by the board of CombiGene AB on 22 August 2018 to introduce a preference issue of units (”the Issue”). Full subscription of the offer will generate about...
CombiGene announces a 75-percent guaranteed preference issue of units amounting to 31 million kronor
The Board of Directors of CombiGene AB (publ) (”CombiGene” or ”the Company”) has approved a proposal for a preferential rights issue of shares and warrants (”the Offer” or ”the Rights Issue”). Full subscription of the offer will generate about MSEK 31...
Interim Report January – june 2018
Interim Report >> Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden <a href="https://www.linkedin.com/company/10149155/" target="blank"><i class="fa fa-linkedin fa-3x"...
CombiGene participated in a positive meeting with the European Medicines Agency
EU allocates EUR 3.6 million in funding for development of CombiGene’s cuttingedge gene therapy
Interim Report January-March 2018
Annual Report 2017
CombiGene: New issue registered
CombiGene AB realized a preference share issue in February 2018. The issue raised 2.3 million kronor before issuing expenses. Read more >> Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden <a...
Notice of Annual General Meeting of shareholders in CombiGene AB (publ)
CombiGene: Now we’re strengthening our management team with the addition of Karin Agerman as Chief Research & Development Officer.
During 2018 CombiGene is entering a decisive phase with focus on development of a manufacturing method for our candidate drug, CG01, and continued intensive business development. This will demand a good measure of professionalism and expertise, as well as...
CombiGene: CombiGene’s issue was subscribed to 22.5 percent
The preference share issue, realized during the period 12 February – 28 February 2018, was subscribed to 22.5 percent, 79 percent of which was subscribed with subscription rights. The issue raised 2.3 million kronor in issue capital before issuing expenses...
All of CombiGene’s board and management will subscribe for shares in the new issue.
CombiGene had a very intensive year in 2017, with three successful preclinical studies. Thanks to the positive results from these studies, CombiGene is now preparing for the next important step on our path to an approved drug via our collaboration with...
Final data from long-term study of CombiGene’s epilepsy treatment indicate clearly positive effects in the form of fewer and shorter seizures.
Final data from CombiGene’s preclinical proof-of-concept-study (the long-term study) show that CombiGene’s candidate drug, CG01, has clear antiepileptic effects. The study has demonstrated that CG01 reduces the frequency and duration of epileptic seizures...
CombiGene AB publishes memorandum
CombiGene AB publishes this memorandum pursuant to a resolution by the board of CombiGene AB on 22 January to introduce a preference share issue which was authorized by the Annual General Meeting on 9 May 2017. The new issue is a preference share issue,...
CombiGene establishes UK subsidiary to secure close and effective collaboration with Cell and Gene Therapy Catapult
Year-end statement January-December 2017
CombiGene AB (publ) presents the year-end statement for 2017 at an earlier date than planned
CombiGene’s board approves preferential rights issue
CombiGene and Cell and Gene Therapy Catapult sign agreement to develop manufacturing process for novel gene therapy to treat epilepsy
Collaboration between Cell and Gene Therapy Catapult (CGT Catapult) and Swedish gene therapy company CombiGene will take a unique therapy one step closer to helping sufferers of hard to treat epilepsy. Read more >> Combigene AB, Medicon Village,...
About CombiGene
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.
The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.